Guggenheim on Dianthus (DNTH) and Leads BioLabs Deal: 'We view this as a well-structured deal'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $100.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst comments "Today ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
